{"id":280,"date":"2010-08-09T13:33:18","date_gmt":"2010-08-09T13:33:18","guid":{"rendered":"http:\/\/www.whistleblowerlawyerblog.com\/2010\/08\/merck_and_other_pharma_compani.html"},"modified":"2021-06-11T17:47:51","modified_gmt":"2021-06-11T21:47:51","slug":"merck_and_other_pharma_compani","status":"publish","type":"post","link":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/","title":{"rendered":"Merck and Other Pharma Companies Probed by DOJ and SEC in Foreign Corrupt Practices Act (FCPA) Investigation"},"content":{"rendered":"

When Pharma manufacturers are targeted by the Department of Justice, qui tam<\/em> whistleblower cases under the False Claims Act <\/a>are often the reason.<\/p>\n

Now, whistleblowers may also receive rewards for reporting violations of the Foreign Corrupt Practices Act (FCPA), thanks to the new whistleblower provisions of the Wall Street financial reform law<\/a>. Announcements like Merck’s recent SEC filing that it is now the subject an FCPA investigation involving other Pharma companies should become common, as corruption will now be increasingly exposed in a new wave of SEC Whistleblower cases.<\/a><\/p>\n

The recent 10-Q filing of Merck & Co., Inc. <\/a>stated in part: <\/p>\n

The Company has received letters from the DOJ and the SEC that seek information about activities in a number of countries and reference the Foreign Corrupt Practices Act. The Company is cooperating with the agencies in their requests and believes that this inquiry is part of a broader review of pharmaceutical industry practices in foreign countries.<\/em><\/p>\n

As we have followed through its development, the Dodd-Frank financial reform law created the new SEC Whistleblower <\/a>and CFTC Whistleblower <\/a>programs, which will include FCPA cases.<\/p>\n

The FCPA, as we have discussed previously, prohibits bribery of foreign government officials <\/a>in international business transactions, and false entries in books and records of those companies within the statute. Whistleblowers who assist the SEC recover monetary sanctions in FCPA cases now have an enforceable right to a monetary award of 10-30%<\/a>.<\/p>\n

Pharma’s exposure for any bribes and kickbacks abroad are a ripe subject for FCPA enforcement.
\n Continue reading \u2192<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

When Pharma manufacturers are targeted by the Department of Justice, qui tam whistleblower cases under the False Claims Act are often the reason. Now, whistleblowers may also receive rewards for reporting violations of the Foreign Corrupt Practices Act (FCPA), thanks to the new whistleblower provisions of the Wall Street financial reform law. Announcements like Merck’s […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,10,12],"tags":[],"class_list":["post-280","post","type-post","status-publish","format-standard","hentry","category-false-claims-act","category-pharmaceutical-fraud","category-sec-whistleblower-program-cftc-whistleblower-program"],"yoast_head":"\nMerck and Other Pharma Companies Probed by DOJ and SEC in Foreign Corrupt Practices Act (FCPA) Investigation — Whistleblower Lawyer Blog — August 9, 2010<\/title>\n<meta name=\"description\" content=\"When Pharma manufacturers are targeted by the Department of Justice, qui tam whistleblower cases under the False Claims Act are often the reason. Now, — August 9, 2010\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Merck and Other Pharma Companies Probed by DOJ and SEC in Foreign Corrupt Practices Act (FCPA) Investigation — Whistleblower Lawyer Blog — August 9, 2010\" \/>\n<meta name=\"twitter:description\" content=\"When Pharma manufacturers are targeted by the Department of Justice, qui tam whistleblower cases under the False Claims Act are often the reason. Now, — August 9, 2010\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Sullivan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Other Pharma Companies Probed by DOJ and SEC in Foreign Corrupt Practices Act (FCPA) Investigation — Whistleblower Lawyer Blog — August 9, 2010","description":"When Pharma manufacturers are targeted by the Department of Justice, qui tam whistleblower cases under the False Claims Act are often the reason. Now, — August 9, 2010","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/","twitter_card":"summary_large_image","twitter_title":"Merck and Other Pharma Companies Probed by DOJ and SEC in Foreign Corrupt Practices Act (FCPA) Investigation — Whistleblower Lawyer Blog — August 9, 2010","twitter_description":"When Pharma manufacturers are targeted by the Department of Justice, qui tam whistleblower cases under the False Claims Act are often the reason. Now, — August 9, 2010","twitter_misc":{"Written by":"Michael Sullivan","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/#article","isPartOf":{"@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/"},"author":{"name":"Michael Sullivan","@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/#\/schema\/person\/06cb979e5d74ec7f83f73b757da4331f"},"headline":"Merck and Other Pharma Companies Probed by DOJ and SEC in Foreign Corrupt Practices Act (FCPA) Investigation","datePublished":"2010-08-09T13:33:18+00:00","dateModified":"2021-06-11T21:47:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/"},"wordCount":460,"articleSection":["False Claims Act","Pharmaceutical Fraud","SEC Whistleblower Program & CFTC Whistleblower Program"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/","url":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/","name":"Merck and Other Pharma Companies Probed by DOJ and SEC in Foreign Corrupt Practices Act (FCPA) Investigation — Whistleblower Lawyer Blog — August 9, 2010","isPartOf":{"@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/#website"},"datePublished":"2010-08-09T13:33:18+00:00","dateModified":"2021-06-11T21:47:51+00:00","author":{"@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/#\/schema\/person\/06cb979e5d74ec7f83f73b757da4331f"},"description":"When Pharma manufacturers are targeted by the Department of Justice, qui tam whistleblower cases under the False Claims Act are often the reason. Now, — August 9, 2010","breadcrumb":{"@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/merck_and_other_pharma_compani\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/"},{"@type":"ListItem","position":2,"name":"Merck and Other Pharma Companies Probed by DOJ and SEC in Foreign Corrupt Practices Act (FCPA) Investigation"}]},{"@type":"WebSite","@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/#website","url":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/","name":"Whistleblower Lawyer Blog","description":"Published by Whistleblower Attorneys \u2014 Finch McCranie, LLP","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/#\/schema\/person\/06cb979e5d74ec7f83f73b757da4331f","name":"Michael Sullivan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1c20f28ef8779909ce4423e28badc00a489c680349138c20442a37fb45a0e8cf?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1c20f28ef8779909ce4423e28badc00a489c680349138c20442a37fb45a0e8cf?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1c20f28ef8779909ce4423e28badc00a489c680349138c20442a37fb45a0e8cf?s=96&d=mm&r=g","caption":"Michael Sullivan"},"sameAs":["https:\/\/www.finchmccranie.com\/michael-a-sullivan.html"]}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/wp-json\/wp\/v2\/posts\/280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/wp-json\/wp\/v2\/comments?post=280"}],"version-history":[{"count":1,"href":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/wp-json\/wp\/v2\/posts\/280\/revisions"}],"predecessor-version":[{"id":1990,"href":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/wp-json\/wp\/v2\/posts\/280\/revisions\/1990"}],"wp:attachment":[{"href":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/wp-json\/wp\/v2\/media?parent=280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/wp-json\/wp\/v2\/categories?post=280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.finchmccranie.com\/whistleblower-blog\/wp-json\/wp\/v2\/tags?post=280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}